Aprea Therapeutics Inc

Research Aprea Therapeutics Inc (APRE) on Bullrun: market cap USD 10.14M. Explore financials, valuation history, model signals, and stock context.

Key Metrics

• TickerAPRE
• ExchangeNASDAQ
• CountryUnited States
• SectorHealthcare
• IndustryBiotechnology
• CurrencyUSD
• Market capUSD 10.14M
• Financial periodFY2025
• Net income-USD 12.60M

Valuation Snapshot

latest market cap is USD 10.14M.

About Aprea Therapeutics Inc

Aprea Therapeutics, Inc., a clinical-stage biopharmaceutical company, focuses on developing and commercializing novel synthetic lethality-based cancer therapeutics that targets DNA damage response pathways. Its lead product candidates are APR-1051, an orally bioavailable small-molecule inhibitor of WEE1 kinase that is in Phase 1 clinical trial for the treatment of patients with advanced solid tumors with biomarkers and ATRN-119, an ATR inhibitor, which is in Phase 1/2a clinical trial for solid tumor indications.

Frequently asked questions

What is Aprea Therapeutics Inc's market cap?

Aprea Therapeutics Inc's market capitalization is USD 10.14M.

What does Aprea Therapeutics Inc do?

Aprea Therapeutics, Inc., a clinical-stage biopharmaceutical company, focuses on developing and commercializing novel synthetic lethality-based cancer therapeutics that targets DNA damage response pathways.